secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2026-08-12T20:13:33+00:00
Accession:  0001835268-26-000027
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Connect Biopharma Q2 net loss $17.3M; enrollment done in both Seabreeze STAT trials
--------------------------------------------------------------------------------

- Q2 2026 net loss $17.3M ($0.27/share) vs $12.9M ($0.23) in Q2 2025; H1 loss $36.7M ($0.61).
- Cash, equivalents, short-term investments $31.5M at June 30, 2026; runway at least one year.
- Enrollment completed in Phase 2 Seabreeze STAT asthma (160 pts) and COPD (159 pts) studies; topline results expected September 2026.
- Initiated open-label Phase 2 Seabreeze STAT IV trial (40 participants) evaluating IV rademikibart for acute exacerbations.
- Simcere license revenue $2.8M in Q2 (vs $48K prior year); eligible for up to ~$99M in remaining milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000027/0001835268-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000027/cntb-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001835268-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer